{"id":"meningococcal-c","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain/erythema"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"}]},"_chembl":null,"_dailymed":{"setId":"fd5652b6-5ae4-437e-a456-47deaf500794","title":"PENBRAYA (MENINGOCOCCAL GROUPS A, B, C, W, AND Y VACCINE) KIT [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified polysaccharide from the meningococcal C capsule conjugated to a protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugation allows for improved antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by serogroup C strains.","oneSentence":"Meningococcal C conjugate vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C polysaccharide capsule.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:51:36.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT05935176","phase":"PHASE4","title":"Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-09-20","conditions":"Epidemic Meningitis","enrollment":660},{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT06834100","phase":"PHASE3","title":"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","status":"RECRUITING","sponsor":"NPO Petrovax","startDate":"2025-02-12","conditions":"Infections, Meningococcal","enrollment":240},{"nctId":"NCT07197762","phase":"PHASE4","title":"MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-11-04","conditions":"Neisseria Meningitidis","enrollment":125},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT04843111","phase":"","title":"Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)","status":"RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-05","conditions":"Meningococcal Infection","enrollment":50},{"nctId":"NCT07204457","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old","status":"RECRUITING","sponsor":"EyeGene Inc.","startDate":"2025-10-15","conditions":"Meningococcal Infections","enrollment":1123},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT04166656","phase":"PHASE3","title":"Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-09-15","conditions":"Splenectomy","enrollment":84},{"nctId":"NCT04825223","phase":"PHASE1","title":"Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-29","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":576},{"nctId":"NCT06228586","phase":"PHASE3","title":"Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-01-18","conditions":"Meningococcal Infection, Healthy Volunteers","enrollment":447},{"nctId":"NCT04368429","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-22","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":360},{"nctId":"NCT04084769","phase":"PHASE3","title":"Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-03","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":570},{"nctId":"NCT03890367","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-12","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":707},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT04142242","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-04","conditions":"Meningococcal Infection (Healthy Volunteers)","enrollment":471},{"nctId":"NCT04936685","phase":"PHASE3","title":"Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-08-23","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":209},{"nctId":"NCT04886154","phase":"PHASE1, PHASE2","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-14","conditions":"Infections, Meningococcal","enrollment":1440},{"nctId":"NCT03295318","phase":"PHASE2","title":"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-11-15","conditions":"Meningitis, Meningococcal","enrollment":375},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT04061382","phase":"","title":"Sero-epidemiological Survey of England in 2019/2020 - COVID-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-10-15","conditions":"Serogroup C Meningococcal Meningitis, Diphtheria, COVID-19","enrollment":2963},{"nctId":"NCT03869866","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-04-09","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":290},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04143061","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-12-30","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":1328},{"nctId":"NCT04440176","phase":"PHASE2","title":"A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":309},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT05252715","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-18","conditions":"Meningitis, Meningococcal","enrollment":1200},{"nctId":"NCT06314659","phase":"PHASE3","title":"Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-17","conditions":"Healthy Population","enrollment":630},{"nctId":"NCT06314685","phase":"PHASE3","title":"Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-12-10","conditions":"Healthy Population","enrollment":2450},{"nctId":"NCT06337071","phase":"PHASE2","title":"A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1200},{"nctId":"NCT04645966","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2020-11-26","conditions":"Meningococcal Vaccine","enrollment":326},{"nctId":"NCT04502693","phase":"PHASE3","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2020-08-14","conditions":"Infections, Meningococcal","enrollment":3657},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT05739292","phase":"PHASE1","title":"Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2023-02-28","conditions":"Infection, Meningococcal","enrollment":60},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT06165276","phase":"PHASE1","title":"A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07-25","conditions":"Meningococcal Immunization","enrollment":285},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03135834","phase":"PHASE3","title":"A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-04-24","conditions":"Meningococcal Vaccine","enrollment":1610},{"nctId":"NCT03493919","phase":"PHASE4","title":"A Sourcing Study to Collect Human Blood Samples From Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-08","conditions":"Meningitis, Meningococcal","enrollment":1021},{"nctId":"NCT04450498","phase":"PHASE4","title":"A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2020-12-23","conditions":"Neisseria Meningitides Meningitis","enrollment":260},{"nctId":"NCT04440163","phase":"PHASE3","title":"MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Meningococcal Vaccine","enrollment":2431},{"nctId":"NCT01693380","phase":"PHASE4","title":"Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-05","conditions":"Influenza, Acute Respiratory Infection","enrollment":1742},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT03636906","phase":"PHASE1, PHASE2","title":"Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-04-08","conditions":"Respiratory Syncytial Virus Infections","enrollment":201},{"nctId":"NCT02509494","phase":"PHASE3","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-30","conditions":"Ebola Virus Disease","enrollment":1023},{"nctId":"NCT02699840","phase":"","title":"Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":100},{"nctId":"NCT02864927","phase":"PHASE4","title":"Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-21","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1311},{"nctId":"NCT01890759","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-06-25","conditions":"Meningitis, Meningococcal Infection","enrollment":300},{"nctId":"NCT03476135","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-02-27","conditions":"Meningococcal Infections","enrollment":91},{"nctId":"NCT02842866","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":907},{"nctId":"NCT02955797","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-24","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":918},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT02752906","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-04-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":810},{"nctId":"NCT02842853","phase":"PHASE3","title":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":3344},{"nctId":"NCT01732627","phase":"PHASE2","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-11-12","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":301},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT03205358","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-03-31","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":188},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03077438","phase":"PHASE3","title":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-17","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1000},{"nctId":"NCT01187433","phase":"PHASE2","title":"Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":150},{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT05229536","phase":"PHASE2","title":"Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2018-12-21","conditions":"Meningitis, Meningococcal","enrollment":720},{"nctId":"NCT00459316","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06","conditions":"HIV Infections, Meningitis","enrollment":384},{"nctId":"NCT04714229","phase":"PHASE1","title":"Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old","status":"COMPLETED","sponsor":"EuBiologics Co.,Ltd","startDate":"2020-09-01","conditions":"Infection, Meningococcal","enrollment":60},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT04358731","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-27","conditions":"Vaccine for Meningococcal Disease","enrollment":1640},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03964012","phase":"PHASE3","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-08-20","conditions":"Meningococcal Meningitis","enrollment":1800},{"nctId":"NCT02810340","phase":"PHASE1","title":"Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2016-08-01","conditions":"Meningococcal Vaccines","enrollment":60},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT04689191","phase":"PHASE3","title":"A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine","status":"UNKNOWN","sponsor":"Wei Cun","startDate":"2020-09-15","conditions":"Meningitis, Meningococcal","enrollment":1280},{"nctId":"NCT03189745","phase":"PHASE3","title":"A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-08-01","conditions":"Meningococcal ACWY Disease","enrollment":229},{"nctId":"NCT01896596","phase":"PHASE4","title":"Hepatitis B Vaccination in Infants","status":"COMPLETED","sponsor":"Public Health England","startDate":"2013-07","conditions":"Meningococcal Disease, Pneumococcal Disease, Haemophilus Influenzae Serotype b Disease","enrollment":300},{"nctId":"NCT00197808","phase":"PHASE4","title":"Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines","status":"COMPLETED","sponsor":"Public Health England","startDate":"2005-04","conditions":"Pneumococcal Infections, Meningococcal Infections","enrollment":392},{"nctId":"NCT01192997","phase":"PHASE2, PHASE3","title":"Comparison of Two Meningococcal ACWY Conjugate Vaccines","status":"COMPLETED","sponsor":"Public Health England","startDate":"2012-06","conditions":"Meningococcal Meningitis","enrollment":91},{"nctId":"NCT01272180","phase":"PHASE2","title":"Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-08","conditions":"Invasive Meningococcal Disease","enrollment":484},{"nctId":"NCT00454987","phase":"PHASE4","title":"Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-16","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine","enrollment":288},{"nctId":"NCT02811120","phase":"","title":"PRIME Follow up - Quadri Meningo Vacinees","status":"COMPLETED","sponsor":"Public Health England","startDate":"2016-12","conditions":"Meningococcal Disease","enrollment":57},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT04236960","phase":"PHASE1","title":"Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2018-07-17","conditions":"Meningococcal Infections","enrollment":100},{"nctId":"NCT00352963","phase":"PHASE3","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09-30","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":480},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":373,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Meningococcal C","genericName":"Meningococcal C","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Meningococcal C conjugate vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup C polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}